Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia

Gagan Fervaha, Christina Hill, Ofer Agid, Hiroyoshi Takeuchi, George Foussias, Ishraq Siddiqui, Robert S. Kern, Gary Remington

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND: Although many comprehensive batteries exist to evaluate the nature and degree of cognitive impairments in patients with schizophrenia, short batteries hold promise for rapidly screening and estimating deficits in global cognition. Recently, the Brief Neurocognitive Assessment (BNA) was established and has been shown to have similar validity and utility to a more comprehensive battery of cognitive tests in evaluating global cognitive impairments in patients with schizophrenia. The present study sought to further establish the validity of the BNA by comparing it with the MATRICS Consensus Cognitive Battery (MCCB). METHODS: One-hundred seventy-six patients with schizophrenia and 300 healthy volunteers participated in the present study. Global cognition was evaluated using the MCCB composite score and estimated using the BNA. To examine practice effects and test-retest reliability, patients were re-assessed after 4weeks. RESULTS: The BNA was highly correlated with global cognition as evaluated by the MCCB in both the schizophrenia (r=0.82) and healthy control samples (r=0.75). Both instruments were similarly sensitive to deficits in global cognition in patients with schizophrenia relative to healthy controls. The BNA also demonstrated high test-retest reliability in patients with schizophrenia (r=0.87), comparable to the level observed with the MCCB (r=0.91). In addition, both the BNA and MCCB showed a similar level of practice effects (both Cohen's d=0.11), and both instruments demonstrated equivalent sensitivities to longitudinal change. Furthermore, scores from the BNA and MCCB were related to symptom severity and functional capacity to a similar degree. CONCLUSIONS: The BNA provides clinicians and researchers with an efficient and reliable means by which to evaluate global neurocognitive impairments in patients with schizophrenia by allowing estimation of performance on a more comprehensive standardized battery.

Original languageEnglish
Pages (from-to)304-309
Number of pages6
JournalSchizophrenia Research
Volume166
Issue number1-3
DOIs
Publication statusPublished - 2014 Nov 18
Externally publishedYes

Fingerprint

Schizophrenia
Consensus
Cognition
Reproducibility of Results
Healthy Volunteers
Research Personnel

Keywords

  • Functional competence
  • Generalized cognitive impairment
  • Neuropsychological testing
  • Processing speed
  • Psychosis
  • Reliable change index
  • Working memory

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. / Fervaha, Gagan; Hill, Christina; Agid, Ofer; Takeuchi, Hiroyoshi; Foussias, George; Siddiqui, Ishraq; Kern, Robert S.; Remington, Gary.

In: Schizophrenia Research, Vol. 166, No. 1-3, 18.11.2014, p. 304-309.

Research output: Contribution to journalArticle

Fervaha, G, Hill, C, Agid, O, Takeuchi, H, Foussias, G, Siddiqui, I, Kern, RS & Remington, G 2014, 'Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia', Schizophrenia Research, vol. 166, no. 1-3, pp. 304-309. https://doi.org/10.1016/j.schres.2015.05.015
Fervaha, Gagan ; Hill, Christina ; Agid, Ofer ; Takeuchi, Hiroyoshi ; Foussias, George ; Siddiqui, Ishraq ; Kern, Robert S. ; Remington, Gary. / Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. In: Schizophrenia Research. 2014 ; Vol. 166, No. 1-3. pp. 304-309.
@article{aec5b02e5ea7409bba4491be89728bd2,
title = "Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia",
abstract = "BACKGROUND: Although many comprehensive batteries exist to evaluate the nature and degree of cognitive impairments in patients with schizophrenia, short batteries hold promise for rapidly screening and estimating deficits in global cognition. Recently, the Brief Neurocognitive Assessment (BNA) was established and has been shown to have similar validity and utility to a more comprehensive battery of cognitive tests in evaluating global cognitive impairments in patients with schizophrenia. The present study sought to further establish the validity of the BNA by comparing it with the MATRICS Consensus Cognitive Battery (MCCB). METHODS: One-hundred seventy-six patients with schizophrenia and 300 healthy volunteers participated in the present study. Global cognition was evaluated using the MCCB composite score and estimated using the BNA. To examine practice effects and test-retest reliability, patients were re-assessed after 4weeks. RESULTS: The BNA was highly correlated with global cognition as evaluated by the MCCB in both the schizophrenia (r=0.82) and healthy control samples (r=0.75). Both instruments were similarly sensitive to deficits in global cognition in patients with schizophrenia relative to healthy controls. The BNA also demonstrated high test-retest reliability in patients with schizophrenia (r=0.87), comparable to the level observed with the MCCB (r=0.91). In addition, both the BNA and MCCB showed a similar level of practice effects (both Cohen's d=0.11), and both instruments demonstrated equivalent sensitivities to longitudinal change. Furthermore, scores from the BNA and MCCB were related to symptom severity and functional capacity to a similar degree. CONCLUSIONS: The BNA provides clinicians and researchers with an efficient and reliable means by which to evaluate global neurocognitive impairments in patients with schizophrenia by allowing estimation of performance on a more comprehensive standardized battery.",
keywords = "Functional competence, Generalized cognitive impairment, Neuropsychological testing, Processing speed, Psychosis, Reliable change index, Working memory",
author = "Gagan Fervaha and Christina Hill and Ofer Agid and Hiroyoshi Takeuchi and George Foussias and Ishraq Siddiqui and Kern, {Robert S.} and Gary Remington",
year = "2014",
month = "11",
day = "18",
doi = "10.1016/j.schres.2015.05.015",
language = "English",
volume = "166",
pages = "304--309",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia

AU - Fervaha, Gagan

AU - Hill, Christina

AU - Agid, Ofer

AU - Takeuchi, Hiroyoshi

AU - Foussias, George

AU - Siddiqui, Ishraq

AU - Kern, Robert S.

AU - Remington, Gary

PY - 2014/11/18

Y1 - 2014/11/18

N2 - BACKGROUND: Although many comprehensive batteries exist to evaluate the nature and degree of cognitive impairments in patients with schizophrenia, short batteries hold promise for rapidly screening and estimating deficits in global cognition. Recently, the Brief Neurocognitive Assessment (BNA) was established and has been shown to have similar validity and utility to a more comprehensive battery of cognitive tests in evaluating global cognitive impairments in patients with schizophrenia. The present study sought to further establish the validity of the BNA by comparing it with the MATRICS Consensus Cognitive Battery (MCCB). METHODS: One-hundred seventy-six patients with schizophrenia and 300 healthy volunteers participated in the present study. Global cognition was evaluated using the MCCB composite score and estimated using the BNA. To examine practice effects and test-retest reliability, patients were re-assessed after 4weeks. RESULTS: The BNA was highly correlated with global cognition as evaluated by the MCCB in both the schizophrenia (r=0.82) and healthy control samples (r=0.75). Both instruments were similarly sensitive to deficits in global cognition in patients with schizophrenia relative to healthy controls. The BNA also demonstrated high test-retest reliability in patients with schizophrenia (r=0.87), comparable to the level observed with the MCCB (r=0.91). In addition, both the BNA and MCCB showed a similar level of practice effects (both Cohen's d=0.11), and both instruments demonstrated equivalent sensitivities to longitudinal change. Furthermore, scores from the BNA and MCCB were related to symptom severity and functional capacity to a similar degree. CONCLUSIONS: The BNA provides clinicians and researchers with an efficient and reliable means by which to evaluate global neurocognitive impairments in patients with schizophrenia by allowing estimation of performance on a more comprehensive standardized battery.

AB - BACKGROUND: Although many comprehensive batteries exist to evaluate the nature and degree of cognitive impairments in patients with schizophrenia, short batteries hold promise for rapidly screening and estimating deficits in global cognition. Recently, the Brief Neurocognitive Assessment (BNA) was established and has been shown to have similar validity and utility to a more comprehensive battery of cognitive tests in evaluating global cognitive impairments in patients with schizophrenia. The present study sought to further establish the validity of the BNA by comparing it with the MATRICS Consensus Cognitive Battery (MCCB). METHODS: One-hundred seventy-six patients with schizophrenia and 300 healthy volunteers participated in the present study. Global cognition was evaluated using the MCCB composite score and estimated using the BNA. To examine practice effects and test-retest reliability, patients were re-assessed after 4weeks. RESULTS: The BNA was highly correlated with global cognition as evaluated by the MCCB in both the schizophrenia (r=0.82) and healthy control samples (r=0.75). Both instruments were similarly sensitive to deficits in global cognition in patients with schizophrenia relative to healthy controls. The BNA also demonstrated high test-retest reliability in patients with schizophrenia (r=0.87), comparable to the level observed with the MCCB (r=0.91). In addition, both the BNA and MCCB showed a similar level of practice effects (both Cohen's d=0.11), and both instruments demonstrated equivalent sensitivities to longitudinal change. Furthermore, scores from the BNA and MCCB were related to symptom severity and functional capacity to a similar degree. CONCLUSIONS: The BNA provides clinicians and researchers with an efficient and reliable means by which to evaluate global neurocognitive impairments in patients with schizophrenia by allowing estimation of performance on a more comprehensive standardized battery.

KW - Functional competence

KW - Generalized cognitive impairment

KW - Neuropsychological testing

KW - Processing speed

KW - Psychosis

KW - Reliable change index

KW - Working memory

UR - http://www.scopus.com/inward/record.url?scp=84942373092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942373092&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2015.05.015

DO - 10.1016/j.schres.2015.05.015

M3 - Article

C2 - 26004693

AN - SCOPUS:84942373092

VL - 166

SP - 304

EP - 309

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -